Heart IT has released its WebPaxUniversal Viewer as an addition to its product portfolio. The new system allows hospitals and clinics to add Web-based, fully diagnostic image viewing to their existing infrastructure for both radiology as well as complex moving cardiology images. The WebPax Universal Viewer offers the same Web-based, zero-footprint image viewing technology that was first developed and patented by Heart Imaging Technologies.


nContact Inc. said it received conditional approval for an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, a condition that disrupts the ability of the atria (upper chambers of the heart) to beat regularly and pump blood efficiently. The CONVERGE study, designed to investigate the epicardial/endocardial Convergent Procedure, combines the cardiac ablation expertise, techniques, and technologies of both electrophysiologists and cardiothoracic surgeons.

Biosense Webster Inc. announced the 12-month safety and effectiveness results of the Thermocool Smarttouch catheter and software module in the treatment of symptomatic, drug refractory, paroxysmal atrial fibrillation (AF) from the SMART-AF investigational device exemption (IDE) clinical trial. The results were presented at the Heart Rhythm Society’s 34th Annual Scientific Sessions by Andrea Natale, M.D., a member of the study advisory committee and executive medical director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas.

CardioPET

The next generation of positron emission tomography (PET) imaging agents will herald an age when PET will eclipse single photon emission computed tomography (SPECT) as the “go to” modality for molecular imaging. It will do so by enabling personalized medicine through precision diagnostics, the ability to be delivered cost-effectively in a manner with less radiation to patients, by leveraging hardware advances already being commercialized, and by taking advantage of the extra throughput capacity present in the U.S. installed base of PET/CT scanners.

Toshiba America Medical Systems Inc. offers electrophysiology (EP) clinicians an Infinix-i cardiovascular X-ray system tailored for EP procedures with a new package of features, accessories and technologies. This package maximizes room utilization, improves workflow and enhances safety.

Nanostim, pacemaker

The first patient tests of a new leadless pacemaker show that the device can deliver the same life-saving therapy as a traditional single-chamber pacemaker without potential lead-related complications. The findings are part of the LEADLESS trial and were released at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.

Wearable cardioverter defibrillators (WCD) can be an effective therapy option for patients with a transient or undefined arrhythmic risk, according to the WEARIT-II Registry, the largest prospective study to track patients with the device in a real-world setting. The new findings show that WCDs can serve as a bridging therapy and help avoid unnecessary permanent implantation of defibrillators in patients who ultimately may not need them.

Biotronik announced the U.S. Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D) series. The devices are smaller, thinner and lighter than previous systems.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now